William P. Harris, MD of Seattle Cancer Care Alliance explains some of the common questions asked regarding the phase II trial on pancreatic cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 4008: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).
Advertisement